SLSN · Solesence, Inc. Common Stock

Solesence’s Q1 2026 results reflect an intentional inflection point in its strategic execution: revenue declined 11% year-over-year to $12.957 million, consistent with management’s stated focus on operational discipline over short-term growth. The $766 thousand net loss—versus $80 thousand net income in Q1 2025—was driven by elevated selling, general and administrative expense ($2.799 million vs. $2.108 million) and R&D spending ($1.042 million vs. $1.018 million), both tied to organizational restructuring, employee training, and infrastructure investment under the Transform and Transcend initiative. Notably, gross margin expanded 300 bps to 26%, confirming early traction in operational excellence, even as cost of revenue included higher depreciation and non-cash equity compensation. Adjusted EBITDA fell sharply to ($107) thousand from $609 thousand, underscoring the magnitude of near-term investments. Management explicitly framed these costs as foundational: CFO Laura Riffner stated they created 'near-term pressure on profitability' but delivered 'improved efficiency and reduced labor costs across the business', with expectations for improving operational and financial results through the remainder of 2026. The press release also highlighted commercial progress—including OTC claim expansions via WHSPR™ and Chromalüm™ platforms—and governance enhancements with the addition of independent Director Marc James. With no forward-looking guidance disclosed, investors must assess whether the current margin improvement and structural efficiencies can offset persistent revenue softness and translate into sustained profitability in subsequent quarters.